LRIG2-DT

Across TCGA pan-cancer cohorts, LRIG2-DT RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of LRIG2-DT’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where LRIG2-DT RNA is repressed in tumor relative to normal tissue. In most cancer types LRIG2-DT is over-expressed in tumor, although a few such as THCA and UCEC show the opposite, repressed pattern.

THCA, UCEC, and BLCA are the cancer types where LRIG2-DT tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LRIG2-DT RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Male	III,IV	−0.769	<.001	11	view →
UCEC	All	III,IV	−0.741	<.001	8	view →
BLCA	All	All	−0.328	.002	8	view →
LUSC	All	II,III,IV	−0.242	<.001	7	view →
BRCA	All	III,IV	−0.825	<.001	6	view →
KICH	All	All	−0.329	.003	6	view →
KIRP	Male	All	−0.300	<.001	6	view →
LIHC	Male	II,III,IV	−0.257	<.001	6	view →
LUAD	Female	III,IV	−0.432	<.001	3	view →
CHOL	Male	All	−0.386	.002	2	view →
PRAD	All	All	−0.162	.005	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

LRIG2-DT–THCA

Open the THCA breakdown →